OmniAb, Inc.

OmniAb, Inc. (Nasdaq: OABI) is a biotechnology company focused on antibody discovery, operating a proprietary transgenic animal platform that generates diverse antibody sequences for biopharmaceutical partners. The company reached the public markets in 2022 through a de-SPAC business combination with OmniLit Acquisition Corp., a blank-check vehicle sponsored by OmniLit Sponsor LLC that completed its IPO in 2021 targeting the healthcare and life sciences sector. OmniAb filed its Form 10-Q with the SEC on November 10, 2022, under accession number 0001104659-22-117175, reflecting its early post-merger operating period as an independent public company. For full filings, deal timelines, and sponsor data on OmniAb and hundreds of other SPAC transactions, sign up for complete access at SpacDesk.